On 29 December 2019, Noxopharm submitted a powerful rebuttal of every point raised by the US Patent Examiner for the patent application called Radiotherapy Improvements, and concluded thus:
Summary
In summary, applicant submits that the prior art does not disclose a formulation comprising Idronoxil that would be capable of being delivered to the CNS, let alone treating brain cancer … Reconsideration and withdrawal of the rejection is therefore respectfully requested.
Conclusion
In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance and an early notification to that effect is earnestly solicited
This was a lengthy rebuttal that took the Examiner step-by-step through the key points and in the process proved that Idronoxil dissolved in a lipophilic suppository is both novel and inventive. As this method of delivery is common to all Noxopharm applications, it seems to me that patent approvals are looking good.
NOX Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
